Published in Invest Ophthalmol Vis Sci on July 01, 2006
Biopsy techniques and yields in diagnosing primary intraocular lymphoma. Int Ophthalmol (2007) 1.31
Pathophysiology of retinal lymphoma. Ocul Immunol Inflamm (2009) 1.14
Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmol (2007) 0.92
Genetics of primary intraocular tumors. Ocul Immunol Inflamm (2012) 0.80
Primary vitreoretinal lymphoma. Indian J Ophthalmol (2015) 0.79
Vitreous diagnosis in neoplastic diseases. Mediators Inflamm (2012) 0.77
High-resolution genomic copy number profiling of primary intraocular lymphoma by single nucleotide polymorphism microarrays. Cancer Sci (2014) 0.77
Recent progress in the diagnosis and treatment of primary vitreoretinal lymphoma. Taiwan J Ophthalmol (2016) 0.75
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (1990) 14.46
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
Involvement of the bcl-2 gene in human follicular lymphoma. Science (1985) 8.19
Brain tumors. N Engl J Med (2001) 8.13
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 7.57
Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell (1985) 7.29
131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med (2005) 3.38
Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med (1987) 3.07
Primary central nervous system lymphoma. J Neurosurg (1988) 2.75
Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med (1994) 2.50
The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol (2005) 2.42
Cell cycle deregulation in B-cell lymphomas. Blood (2002) 2.41
Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood (1994) 2.38
Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood (2001) 2.35
Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. J Exp Med (1986) 2.21
BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol (2004) 2.20
bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med (1989) 2.18
Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology (1993) 2.10
Uveitis masquerade syndromes. Ophthalmology (2001) 2.02
Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med (1988) 1.99
Intraocular lymphoma. Curr Opin Ophthalmol (2002) 1.96
Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet (1999) 1.96
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood (1997) 1.85
Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clin Lymphoma (2003) 1.77
Primary intraocular lymphoma diagnosed by fine needle aspiration biopsy of a subretinal lesion. Retina (2001) 1.67
Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood (1998) 1.63
Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology (1999) 1.57
Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol (2004) 1.48
LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood (1994) 1.48
Utility of microdissection and polymerase chain reaction for the detection of immunoglobulin gene rearrangement and translocation in primary intraocular lymphoma. Ophthalmology (1998) 1.46
Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma. Ophthalmology (1987) 1.46
Molecular pathophysiology of indolent lymphoma. Haematologica (2000) 1.42
Molecular pathology of primary intraocular lymphoma. Trans Am Ophthalmol Soc (2003) 1.40
Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome. Graefes Arch Clin Exp Ophthalmol (2003) 1.37
Optimal primer selection for clonality assessment by polymerase chain reaction analysis: II. Follicular lymphomas. Hum Pathol (1994) 1.33
The clinical spectrum of ocular lymphoma. Cancer (1993) 1.31
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol (2005) 1.31
BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res (2003) 1.29
Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye (Lond) (2003) 1.17
Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer (1992) 1.16
Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med (2003) 1.08
Diagnosis and management of primary intraocular lymphoma. Hematol Oncol Clin North Am (2005) 1.08
Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood (1994) 1.07
Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma. Ann Intern Med (1988) 0.98
Direct sequence analysis of the 14q+ and 18q- chromosome junctions in follicular lymphoma. Blood (1990) 0.98
Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol (2002) 0.96
Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. J Clin Oncol (1994) 0.91
CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology (2001) 0.90
Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood (1999) 0.89
18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance. Br J Haematol (1989) 0.89
Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma. Invest Ophthalmol Vis Sci (2005) 0.87
The detection of specific gene rearrangements in non-Hodgkin's lymphoma using the polymerase chain reaction. Br J Cancer (1992) 0.83
Classification, pathogenesis and molecular pathology of primary CNS lymphomas. J Neurooncol (1999) 0.83
bcl-2 rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features. Cancer (1993) 0.82
Incidence and prognostic significance of t(14;18) translocation in follicle center cell lymphoma of low and high grade. A report from southern Sweden. Ann Oncol (1995) 0.78
Infrequent BCL10 mutations in B-cell non-Hodgkin's lymphomas. Jpn J Cancer Res (1999) 0.76
Low frequency of BCL10 gene mutations in B-cell non-Hodgkin's lymphoma. Int J Hematol (2001) 0.76
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol (2005) 13.50
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med (2007) 5.41
Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med (2008) 5.25
The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. Invest Ophthalmol Vis Sci (2012) 4.11
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Rapamycin slows aging in mice. Aging Cell (2012) 3.76
Molecular pathology of age-related macular degeneration. Prog Retin Eye Res (2008) 3.35
Age-related macular degeneration. Lancet (2008) 3.34
Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol (2004) 3.28
Idiopathic multifocal choroiditis/punctate inner choroidopathy with acute photoreceptor loss or dysfunction out of proportion to clinically visible lesions. Retina (2015) 3.26
Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol (2008) 2.90
Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet (2010) 2.74
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
Toxoplasma gondii in the peripheral blood of patients with acute and chronic toxoplasmosis. Br J Ophthalmol (2010) 2.50
Prevalence and characteristics of foveal retinal detachment without macular hole in high myopia. Am J Ophthalmol (2003) 2.47
International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm (2009) 2.47
Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest Ophthalmol Vis Sci (2007) 2.36
Fundus autofluorescence imaging of the white dot syndromes. Arch Ophthalmol (2010) 2.26
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23
Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci (2002) 2.19
Genetic factors of age-related macular degeneration. Prog Retin Eye Res (2004) 2.17
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A (2008) 2.07
The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J (2004) 2.04
Intraocular lymphoma. Curr Opin Ophthalmol (2002) 1.96
Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.92
Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol (2009) 1.91
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol (2008) 1.87
Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol (2007) 1.84
The need for standardization of antiretinal antibody detection and measurement. Am J Ophthalmol (2008) 1.83
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology (2009) 1.78
Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology (2003) 1.78
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother (2004) 1.77
Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75
Noncanonical autophagy promotes the visual cycle. Cell (2013) 1.74
Sympathetic ophthalmia: what have we learned? Am J Ophthalmol (2009) 1.73
Dry eye signs and symptoms in women with premature ovarian failure. Arch Ophthalmol (2004) 1.69
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun (2003) 1.66
Immunopathological aspects of age-related macular degeneration. Semin Immunopathol (2008) 1.63
Macrophage polarization in the maculae of age-related macular degeneration: a pilot study. Pathol Int (2011) 1.62
Adverse effects of smoking on patients with ocular inflammation. Br J Ophthalmol (2010) 1.61
Methotrexate for ocular inflammatory diseases. Ophthalmology (2009) 1.58
Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol (2009) 1.57
The role of infectious agents in the etiology of ocular adnexal neoplasia. Surv Ophthalmol (2008) 1.57
Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood (2010) 1.57
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest (2005) 1.56
A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm (2007) 1.53
Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition. Proc Natl Acad Sci U S A (2006) 1.52
Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology (2010) 1.51
Prevalence of posterior subcapsular cataracts in volunteer cytapheresis donors. Transfusion (2010) 1.51
Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J Immunol (2005) 1.50
Vitreous cytokine levels. Ophthalmology (2003) 1.48
The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol (2002) 1.48
Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration. J Transl Med (2011) 1.47
Protean manifestations of pediatric neurosarcoidosis. Can J Ophthalmol (2009) 1.45
{omega}-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study. Am J Clin Nutr (2009) 1.44
An immunologically privileged retinal antigen elicits tolerance: major role for central selection mechanisms. J Exp Med (2003) 1.44
Azathioprine for ocular inflammatory diseases. Am J Ophthalmol (2009) 1.44
A genome-wide association analysis identified a novel susceptible locus for pathological myopia at 11q24.1. PLoS Genet (2009) 1.43
Resolution of autoimmune polyglandular syndrome-associated keratopathy with keratolimbal stem cell transplantation: case report and historical literature review. Cornea (2007) 1.42
Serpiginous choroiditis. Surv Ophthalmol (2005) 1.41
Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A. Blood (2011) 1.41
Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol (2009) 1.41
Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci (2006) 1.41
Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD). Prog Retin Eye Res (2010) 1.39
International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm (2008) 1.38
Natural course of macular retinoschisis in highly myopic eyes without macular hole or retinal detachment. Am J Ophthalmol (2006) 1.38
Pathological findings in eyes with the ganciclovir implant. Ophthalmology (2005) 1.38
Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol (2005) 1.36
Both Th1 and Th17 are immunopathogenic but differ in other key biological activities. J Immunol (2008) 1.36
Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eye. Health Qual Life Outcomes (2004) 1.35
Epidemiology and course of disease in childhood uveitis. Ophthalmology (2009) 1.35
Characteristics of peripapillary detachment in pathologic myopia. Arch Ophthalmol (2006) 1.34
Endogenous IRBP can be dispensable for generation of natural CD4+CD25+ regulatory T cells that protect from IRBP-induced retinal autoimmunity. J Exp Med (2006) 1.34
Choroideremia: new findings from ocular pathology and review of recent literature. Surv Ophthalmol (2009) 1.34
Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care (2005) 1.34
Syphilitic outer retinopathy. Ocul Immunol Inflamm (2013) 1.34
Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease. Arthritis Res Ther (2012) 1.34
Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J Immunol (2002) 1.33
Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology (2005) 1.33
A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. J Clin Invest (2003) 1.32